IL17A and inflammatory bowel disease: Concurrently, Eng inhibited the NF-κB-driven inflammatory cascade, curtailing the overexpression of proinflammatory cytokines (IL-6, TNF-α, IL-1β, and IL-17A) in intestinal mucosa, thereby disrupting the inflammatory-amplification loop characteristic of IBD [42].